SKY-0515 for Huntington's Disease

(FALCON-HD Trial)

This trial tests a new oral medication, SKY-0515, to determine if it can lower harmful proteins and improve symptoms in people with Huntington's Disease (HD). Participants will receive a low, mid, or high dose of SKY-0515, or a placebo (a pill with no active drug). The trial aims to assess whether SKY-0515 can alleviate symptoms in those with HD. Eligible participants have HD confirmed by genetic testing and can still perform daily tasks independently. As a combined Phase 2 and Phase 3 trial, this research measures SKY-0515's effectiveness in an initial group and represents the final step before FDA approval, offering hope for improved treatment options.

The trial does not clearly state if you must stop taking your current medications, but it excludes those taking medications that might interfere with the study. It's best to discuss your specific medications with the trial team.

Research has shown that SKY-0515 is generally safe and well tolerated. Participants in earlier studies did not experience major safety issues. In one study, the highest dose tested led to a 60% decrease in huntingtin, a harmful protein linked to Huntington's Disease, in the blood. Across different dose levels, SKY-0515 demonstrated positive results without serious side effects. This evidence suggests that the treatment is well tolerated by humans.¹²³⁴⁵

Unlike the standard treatments for Huntington's disease, which often focus on managing symptoms through medications like tetrabenazine and antipsychotics, SKY-0515 offers a novel approach. SKY-0515 is unique because it targets the underlying pathways involved in the disease progression, potentially slowing down the degeneration process itself. Researchers are excited about SKY-0515 due to its three-tiered dosing strategy (low, mid, and high doses), allowing them to fine-tune its effectiveness and safety. This innovative approach could offer a more comprehensive and targeted therapy, giving new hope to those affected by Huntington's disease.

Research has shown that SKY-0515 can significantly reduce harmful proteins linked to Huntington's Disease. In some cases, patients experienced up to a 69% decrease in the mutant huntingtin protein, which plays a major role in the disease. This reduction remained consistent over a year of treatment. The drug alters how the body processes the Huntington gene, lowering the protein levels that contribute to the disease. Patients have tolerated the treatment well, with no major safety issues reported. These findings suggest that SKY-0515 has strong potential to help manage symptoms of Huntington's Disease.²³⁴⁵⁶